|
1
|
Orr B and Edwards RP: Diagnosis and
treatment of ovarian cancer. Hematol Oncol Clin North Am.
32:943–964. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gunderson CC and Moore KN: Olaparib: An
oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian
cancer. Future Oncol. 11:747–757. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Corrado G, Salutari V, Palluzzi E,
Distefano MG, Scambia G and Ferrandina G: Optimizing treatment in
recurrent epithelial ovarian cancer. Expert Rev Anticancer Ther.
17:1147–1158. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Platten M, Nollen EAA, Röhrig UF,
Fallarino F and Opitz CA: Tryptophan metabolism as a common
therapeutic target in cancer, neurodegeneration and beyond. Nat Rev
Drug Discov. 18:379–401. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Savitz J: The kynurenine pathway: A finger
in every pie. Mol Psychiatry. 25:131–147. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Venkateswaran N, Lafita-Navarro MC, Hao
YH, Kilgore JA, Perez-Castro L, Braverman J, Borenstein-Auerbach N,
Kim M, Lesner NP, Mishra P, et al: MYC promotes tryptophan uptake
and metabolism by the kynurenine pathway in colon cancer. Genes
Dev. 33:1236–1251. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Puccetti P, Fallarino F, Italiano A,
Soubeyran I, MacGrogan G, Debled M, Velasco V, Bodet D, Eimer S,
Veldhoen M, et al: Accumulation of an endogenous tryptophan-
derived metabolite in colorectal and breast cancers. PLoS One.
10:e01220462015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ball HJ, Yuasa HJ, Austin CJ, Weiser S and
Hunt NH: Indoleamine 2,3-dioxygenase-2; a new enzyme in the
kynurenine pathway. Int J Biochem Cell Biol. 41:467–471. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheong JE and Sun L: Targeting the
IDO1/TDO2-KYN-AhR pathway for cancer immunotherapy-challenges and
opportunities. Trends Pharmacol Sci. 39:307–325. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pham QT, Oue N, Sekino Y, Yamamoto Y,
Shigematsu Y, Sakamoto N, Sentani K, Uraoka N and Yasui W: TDO2
overexpression is associated with cancer stem cells and poor
prognosis in esophageal squamous cell carcinoma. Oncology.
95:297–308. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu M, Wang X, Wang L, Ma X, Gong Z, Zhang
S and Li Y: Targeting the IDO1 pathway in cancer: From bench to
bedside. J Hematol Oncol. 11:1002018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
D'Amato NC, Rogers TJ, Gordon MA, Greene
LI, Cochrane DR, Spoelstra NS, Nemkov TG, D'Alessandro A, Hansen KC
and Richer JK: A TDO2-AhR signaling axis facilitates anoikis
resistance and metastasis in triple-negative breast cancer. Cancer
Res. 75:4651–4664. 2015. View Article : Google Scholar
|
|
13
|
Bishnupuri KS, Alvarado DM, Khouri AN,
Shabsovich M, Chen B, Dieckgraefe BK and Ciorba MA: IDO1 and
kynurenine pathway metabolites activate PI3K-Akt signaling in the
neoplastic colon epithelium to promote cancer cell proliferation
and inhibit apoptosis. Cancer Res. 79:1138–1150. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smith C, Chang MY, Parker KH, Beury DW,
DuHadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP,
Laury-Kleintop LD, et al: IDO is a nodal pathogenic driver of lung
cancer and metastasis development. Cancer Discov. 2:722–735. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pilotte L, Larrieu P, Stroobant V, Colau
D, Dolusic E, Frédérick R, De Plaen E, Uyttenhove C, Wouters J,
Masereel B and Van den Eynde BJ: Reversal of tumoral immune
resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl
Acad Sci USA. 109:2497–2502. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fatokun AA, Hunt NH and Ball HJ:
Indoleamine 2,3- dioxygenase 2 (IDO2) and the kynurenine pathway:
Characteristics and potential roles in health and disease. Amino
Acids. 45:1319–1329. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brenk M, Scheler M, Koch S, Neumann J,
Takikawa O, Häcker G, Bieber T and von Bubnoff D: Tryptophan
deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic
cells favoring the induction of human
CD4+CD25+ Foxp3+ T regulatory
cells. J Immuno. 183:145–154. 2009. View Article : Google Scholar
|
|
18
|
Chen W, Liang X, Peterson AJ, Munn DH and
Blazar BR: The indoleamine 2,3-dioxygenase pathway is essential for
human plasmacytoid dendritic cell-induced adaptive T regulatory
cell generation. J Immunol. 181:5396–5404. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chung DJ, Rossi M, Romano E, Ghith J, Yuan
J, Munn DH and Young JW: Indoleamine 2,3-dioxygenase-expressing
mature human monocyte-derived dendritic cells expand potent
autologous regulatory T cells. Blood. 114:555–563. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Curti A, Pandolfi S, Valzasina B, Aluigi
M, Isidori A, Ferri E, Salvestrini V, Bonanno G, Rutella S, Durelli
I, et al: Modulation of tryptophan catabolism by human leukemic
cells results in the conversion of CD25- into CD25+ T
regulatory cells. Blood. 109:2871–2877. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fallarino F, Grohmann U, You S, McGrath
BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML and
Volpi C: The combined effects of tryptophan starvation and
tryptophan catabolites down-regulate T cell receptor zeta-chain and
induce a regulatory phenotype in naive T cells. J Immunol.
176:6752–6761. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hippen KL, O'Connor RS, Lemire AM, Saha A,
Hanse EA, Tennis NC, Merkel SC, Kelekar A, Riley JL, Levine BL, et
al: In vitro induction of human regulatory T cells using conditions
of low tryptophan plus kynurenines. Am J Transplant. 17:3098–3113.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sharma MD, Baban B, Chandler P, Hou DY,
Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL and Munn DH:
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes
directly activate mature Tregs via indoleamine 2,3-dioxygenase. J
Clin Invest. 117:2570–2582. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kristeleit R, Davidenko I, Shirinkin V,
El-Khouly F, Bondarenko I, Goodheart MJ, Gorbunova V, Penning CA,
Shi JG, Liu X, et al: A randomised, open-label, phase 2 study of
the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as
therapy for biochemically recurrent (CA-125 relapse)-only
epithelial ovarian cancer, primary peritoneal carcinoma, or
fallopian tube cancer. Gynecol Oncol. 146:484–490. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang GN, Zhu Y and Huang JM:
Understanding of targeting MyD88, IDO1 and AHR at the heart of
immunosuppressive signaling pathway for immunotherapy of epithelial
ovarian cancer. Zhonghua fu chan ke za zhi. 53:448–451. 2018.(In
Chinese). PubMed/NCBI
|
|
26
|
Awuah SG, Zheng YR, Bruno PM, Hemann MT
and Lippard SJ: A Pt(IV) pro-drug preferentially targets
indoleamine-2,3-dioxygenase, providing enhanced ovarian cancer
immuno-chemotherapy. J Am Chem Soc. 137:14854–14857. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qian F, Villella J, Wallace PK,
Mhawech-Fauceglia P, Tario JD Jr, Andrews C, Matsuzaki J, Valmori
D, Ayyoub M, Frederick PJ, et al: Efficacy of levo-1-methyl
tryptophan and dextro-1-methyl tryptophan in reversing
indoleamine-2, 3-dioxygenase-mediated arrest of T-cell
proliferation in human epithelial ovarian cancer. Cancer Res.
69:5498–5504. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tanizaki Y, Kobayashi A, Toujima S, Shiro
M, Mizoguchi M, Mabuchi Y, Yagi S, Minami S, Takikawa O and Ino K:
Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of
ovarian cancer by inducing an immunosuppressive environment. Cancer
Sci. 105:966–973. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Uyttenhove C, Pilotte L, Theate I,
Stroobant V, Colau D, Parmentier N, Boon T and Van den Eynde BJ:
Evidence for a tumoral immune resistance mechanism based on
tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med.
9:1269–1274. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Inaba T, Ino K, Kajiyama H, Yamamoto E,
Shibata K, Nawa A, Nagasaka T, Akimoto H, Takikawa O and Kikkawa F:
Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in
the progression of ovarian carcinoma. Gynecol Oncol. 115:185–192.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang D, Saga Y, Mizukami H, Sato N, Nonaka
H, Fujiwara H, Takei Y, Machida S, Takikawa O, Ozawa K and Suzuki
M: Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that
inhibits natural killer cell function, as a useful target for
ovarian cancer therapy. Int J Oncol. 40:929–934. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dolusić E, Larrieu P, Moineaux L,
Stroobant V, Pilotte L, Colau D, Pochet L, Van den Eynde B,
Masereel B, Wouters J and Frédérick R: Tryptophan 2,3-dioxygenase
(TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential
anticancer immunomodulators. J Med Chem. 54:5320–5334. 2011.
View Article : Google Scholar
|
|
33
|
Young T, Mei F, Liu J, Bast RC Jr, Kurosky
A and Cheng X: Proteomics analysis of H-RAS-mediated oncogenic
transformation in a genetically defined human ovarian cancer model.
Oncogene. 24:6174–6184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu J, Yang G, Thompson-Lanza JA, Glassman
A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, et
al: A genetically defined model for human ovarian cancer. Cancer
Res. 64:1655–1663. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Metzgar D, Liu L, Hansen C, Dybvig K and
Wills C: Domain-level differences in microsatellite distribution
and content result from different relative rates of insertion and
deletion mutations. Genome Res. 12:408–413. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li R, Quan Y and Xia W: SIRT3 inhibits
prostate cancer metastasis through regulation of FOXO3A by
suppressing Wnt/β-catenin pathway. Exp Cell Res. 364:143–151. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cory AH, Owen TC, Barltrop JA and Cory JG:
Use of an aqueous soluble tetrazolium/formazan assay for cell
growth assays in culture. Cancer Commun. 3:207–212. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bindea G, Mlecnik B, Tosolini M,
Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T,
Lafontaine L, Berger A, et al: Spatiotemporal dynamics of
intratumoral immune cells reveal the immune landscape in human
cancer. Immunity. 39:782–795. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li L, Feng Q and Wang X: PreMSIm: An R
package for predicting microsatellite instability from the
expression profiling of a gene panel in cancer. Comput Struct
Biotechnol J. 18:668–675. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schmidt SK, Muller A, Heseler K, Woite C,
Spekker K, MacKenzie CR and Däubener W: Antimicrobial and
immunoregulatory properties of human tryptophan 2,3-dioxygenase.
Eur J Immunol. 39:2755–2764. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Greene LI, Bruno TC, Christenson JL,
D'Alessandro A, Culp-Hill R, Torkko K, Borges VF, Slansky JE and
Richer JK: A role for tryptophan-2,3-dioxygenase in CD8 T-cell
suppression and evidence of tryptophan catabolism in breast cancer
patient plasma. Mol Cancer Re. 17:131–139. 2019. View Article : Google Scholar
|
|
43
|
Wardhani LO, Matsushita M, Iwasaki T,
Kuwamoto S, Nonaka D, Nagata K, Kato M, Kitamura Y and Hayashi K:
Expression of the IDO1/TDO2-AhR pathway in tumor cells or the tumor
microenvironment is associated with Merkel cell polyomavirus status
and prognosis in Merkel cell carcinoma. Human Pathol. 84:52–61.
2019. View Article : Google Scholar
|
|
44
|
Rogers TJ, Christenson JL, Greene LI,
O'Neill KI, Williams MM, Gordon MA, Nemkov T, D'Alessandro A,
Degala GD, Shin J, et al: Reversal of triple-negative breast cancer
EMT by miR-200c decreases tryptophan catabolism and a program of
immunosuppression. Mol Cancer Res. 17:30–41. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Badawy AA: Targeting tryptophan
availability to tumors: The answer to immune escape? Immunol Cell
Biol. 96:1026–1034. 2018. View Article : Google Scholar : PubMed/NCBI
|
